The Hidden Health and Economic Burden of Rotavirus Gastroenteritis in Malaysia An Estimation Using Multiple Data Sources

被引:12
|
作者
Loganathan, Tharani [1 ]
Ng, Chiu-Wan [1 ]
Lee, Way-Seah [2 ,3 ]
Jit, Mark [4 ,5 ]
机构
[1] Univ Malaya, Julius Ctr Univ, Dept Social & Prevent Med, Kuala Lumpur 50603, Malaysia
[2] Univ Malaya, Fac Med, Dept Paediat, Kuala Lumpur 50603, Malaysia
[3] Univ Malaya, Paediat & Child Hlth Res Grp, Kuala Lumpur 50603, Malaysia
[4] Publ Hlth England, Modeling & Econ Unit, London, England
[5] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England
关键词
rotavirus; gastroenteritis; burden; morbidity; mortality; cost; vaccine; COST-EFFECTIVENESS; DISEASE BURDEN; DIARRHEA; EPIDEMIOLOGY; HOSPITALIZATION; VACCINATION; INFECTIONS; MORTALITY; ILLNESS; JAPAN;
D O I
10.1097/INF.0000000000001129
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Rotavirus gastroenteritis (RVGE) results in substantial mortality and morbidity worldwide. However, an accurate estimation of the health and economic burden of RVGE in Malaysia covering public, private and home treatment is lacking. Methods: Data from multiple sources were used to estimate diarrheal mortality and morbidity according to health service utilization. The proportion of this burden attributable to rotavirus was estimated from a community-based study and a meta-analysis we conducted of primary hospital-based studies. Rotavirus incidence was determined by multiplying acute gastroenteritis incidence with estimates of the proportion of gastroenteritis attributable to rotavirus. The economic burden of rotavirus disease was estimated from the health systems and societal perspective. Results: Annually, rotavirus results in 27 deaths, 31,000 hospitalizations, 41,000 outpatient visits and 145,000 episodes of home-treated gastroenteritis in Malaysia. We estimate an annual rotavirus incidence of 1 death per 100,000 children and 12 hospitalizations, 16 outpatient clinic visits and 57 home-treated episodes per 1000 children under-5 years. Annually, RVGE is estimated to cost US$ 34 million to the healthcare provider and US$ 50 million to society. Productivity loss contributes almost a third of costs to society. Publicly, privately and home-treated episodes consist of 52%, 27% and 21%, respectively, of the total societal costs. Conclusions: RVGE represents a considerable health and economic burden in Malaysia. Much of the burden lies in privately or home-treated episodes and is poorly captured in previous studies. This study provides vital information for future evaluation of cost-effectiveness, which are necessary for policy-making regarding universal vaccination.
引用
收藏
页码:601 / 606
页数:6
相关论文
共 50 条
  • [1] Epidemiology and economic burden of rotavirus gastroenteritis in hospitals and paediatric clinics in Taiwan, 2005-2006
    Mast, T. Christopher
    Chen, Po-Yen
    Lu, Kun-Chia
    Hsu, Chun-Ming
    Lin, Hsiao Chuan
    Liao, Wen-Chen
    Lin, Da-Pi
    Chen, Hung-Chih
    Lac, Christina
    VACCINE, 2010, 28 (17) : 3008 - 3013
  • [2] The health and economic burden of rotavirus disease in Belgium
    Bilcke, Joke
    Van Damme, Pierre
    De Smet, Frank
    Hanquet, Germaine
    Van Ranst, Marc
    Beutels, Philippe
    EUROPEAN JOURNAL OF PEDIATRICS, 2008, 167 (12) : 1409 - 1419
  • [3] The health and economic burden of rotavirus disease in Belgium
    Joke Bilcke
    Pierre Van Damme
    Frank De Smet
    Germaine Hanquet
    Marc Van Ranst
    Philippe Beutels
    European Journal of Pediatrics, 2008, 167 : 1409 - 1419
  • [4] Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries
    Rheingans, Richard D.
    Constenla, Dagna
    Antil, Lynn
    Innis, Bruce L.
    Breuer, Thomas
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2007, 21 (04): : 192 - 204
  • [5] Burden of Acute Gastroenteritis Hospitalizations and Emergency Department Visits in US Children That Is Potentially Preventable by Rotavirus Vaccination: A Probe Study Using the Now-Withdrawn RotaShield Vaccine
    Tate, Jacqueline E.
    Curns, Aaron T.
    Cortese, Margaret M.
    Weintraub, Eric S.
    Hambidge, Simon
    Zangwill, Kenneth M.
    Patel, Manish M.
    Baggs, James M.
    Parashar, Umesh D.
    PEDIATRICS, 2009, 123 (03) : 744 - 749
  • [6] Using surveillance and economic data to make informed decisions about rotavirus vaccine introduction
    Cohen, Adam L.
    Aliabadi, Negar
    Serhan, Fatima
    Tate, Jacqueline E.
    Zuber, Patrick
    Parashar, Umesh D.
    VACCINE, 2018, 36 (51) : 7755 - 7758
  • [7] Burden of Rotavirus Disease in Norway Using National Registries for Public Health Research
    Bruun, Tone
    Salamanca, Beatriz Valcarcel
    Bekkevold, Terese
    Vainio, Kirsti
    Gibory, Moustafa
    Haugstad, Kirsti Egge
    Rojahn, Astrid
    Jakobsen, Kirsti
    Storvold, Gunnar
    Lunde, Anette
    Stordal, Ketil
    Kanestrom, Anita
    Eidem, Magnhild Owesen
    Dollner, Henrik
    Skanke, Lars Hosoien
    Nordbo, Svein Arne
    Sivertsen, Heidi Christin
    Gilje, Ann Marit
    Haarr, Elisebet
    Flem, Elmira
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (04) : 396 - 400
  • [8] Burden of acute rotavirus gastroenteritis (RV-AGE) in Germany: A comparison of federal statistics and epidemiological data
    Forster, J.
    Hammerschmidt, T.
    GESUNDHEITSWESEN, 2007, 69 (04) : 227 - 232
  • [9] Epidemiology of Rotavirus Gastroenteritis and Rotavirus-Associated Benign Convulsions with Mild Gastroenteritis after the Introduction of Rotavirus Vaccines in South Korea: Nationwide Data from the Health Insurance Review and Assessment Service
    Kim, Dong Hyun
    Lee, Yeong Seok
    Ha, Dong Jun
    Chun, Min Jun
    Kwon, Young Se
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (22) : 1 - 10
  • [10] Estimation of the health and economic burden of neurocysticercosis in India
    Singh, B. B.
    Khatkar, M. S.
    Gill, J. P. S.
    Dhand, N. K.
    ACTA TROPICA, 2017, 165 : 161 - 169